Treatment with PI3K inhibitors may cause cancers to become more aggressive and metastatic

The enzyme PI3K appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target. However, PI3K inhibitors have only shown modest clinical activity. Now, new research shows that treatment with PI3K inhibitors alone may actually make a patient's cancer even worse by promoting more aggressive tumor cell behavior and increasing the cancer's potential of spreading to other organs.